Myriad Genetics (MYGN) Treasury Shares (2014 - 2026)

Myriad Genetics (MYGN) has reported Treasury Shares for 13 consecutive years, with $8.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Treasury Shares rose 74.51% year-over-year to $8.9 million; the TTM figure through Mar 2026 stood at $8.9 million (up 74.51% YoY), while the FY2025 annual figure was $7.1 million, up 33.96% from the prior year.
• Treasury Shares advanced to $8.9 million in Q1 2026 per MYGN's latest filing, from $7.1 million in the prior quarter.
• Across five years, Treasury Shares topped out at $8.9 million in Q1 2026 and bottomed at $3.7 million in Q3 2022.
• Historically, Treasury Shares has averaged $5.4 million across 5 years, with a median of $5.1 million in 2025.
• Annual changes were most pronounced in 2025 — Treasury Shares decreased 8.93% — and 2026, when it soared 74.51%.
• Myriad Genetics' Treasury Shares stood at $3.7 million in 2022, then advanced by 18.92% to $4.4 million in 2023, then grew by 20.45% to $5.3 million in 2024, then soared by 33.96% to $7.1 million in 2025, then gained by 25.35% to $8.9 million in 2026.
• Business Quant data shows MYGN's Treasury Shares at $8.9 million in Q1 2026, $7.1 million in Q4 2025, and $7.5 million in Q3 2025.